Siemens Healthineers Stock Slumps 13% Despite Strong Earnings in 2026
Siemens Healthineers has faced a tough year in the stock market. Between March 2025 and March 2026, its share price fell sharply, hitting a 52-week low of €38.70 and dropping nearly 13% since January. Despite strong first-quarter earnings, broader market pressures and sector volatility have weighed on performance, contrasting with gains seen by rivals like Roche and Novartis.
The company's latest financial report showed solid results, with earnings per share at €10.43 and a market capitalisation of €172.23 billion. Yet, these figures failed to lift investor confidence amid a wider downturn. The SLI index, which tracks European healthcare stocks, fell by 4.88% over the same period, adding to the pressure. Siemens Healthineers also adjusted its dividend, further dampening sentiment.
Analysts remain upbeat, however. JPMorgan kept an 'overweight' rating on the stock, setting a €61.30 price target. Their optimism stems from the company's operational strength, which they argue is currently undervalued. Barclays echoed this view, dismissing the recent decline as temporary and highlighting the firm's long-term fundamentals. Potential catalysts for recovery include improved margins in imaging and laboratory diagnostics. JPMorgan's projections suggest upside if these areas stabilise. A calming of geopolitical tensions, particularly in the Middle East, could also boost the sector. Meanwhile, some investors now see the stock's weakness as a buying opportunity.
Siemens Healthineers trades at around €166.24, down 0.92% on the day, with its 52-week range stretching from €162.00 to €275.65. While the stock has underperformed peers, analyst confidence and operational improvements may yet shift momentum. The coming months will show whether these factors can offset the broader market challenges.
